Two medicines, side by side
Micafungin vs fluconazole
Micafungin and fluconazole are both labeled for fungal infections. Drugs@FDA records approvals of micafungin since 2005 and of fluconazole since 1990. In FDA's classes, micafungin is an echinocandin antifungal and fluconazole an azole antifungal.
Check it at the source: the micafungin FDA label on DailyMed (effective November 8, 2025); the fluconazole FDA label on DailyMed (effective April 7, 2026).
Highlights of the micafungin record
Micafungin (Mycamine) · label of November 8, 2025
Used for
From the label: indicationsMicafungin for injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies ( 14.1 ) and Use in Specific Populations ( 8.4 )]. […]
On the market
- Earliest approval on file
- March 16, 2005
- Generic labelers
- 10 labelers
- Pharmacy cost
- Not in the survey
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 4
Highlights of the fluconazole record
Fluconazole (Diflucan) · label of April 7, 2026
Used for
From the label: indicationsFluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. […]
On the market
- Earliest approval on file
- January 29, 1990
- Generic labelers
- 41 labelers
- Pharmacy cost
- $0.380 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 18
Source: FDA drug labels via openFDA (Micafungin label of November 8, 2025, Fluconazole label of April 7, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do micafungin and fluconazole differ on the record?
In FDA's classes, micafungin is an echinocandin antifungal and fluconazole an azole antifungal.
Generics: micafungin since 2019; fluconazole since 2004 (Drugs@FDA).
| Micafungin | Fluconazole | |
|---|---|---|
| Labeled for | Fungal infections | Fungal infections, Urinary tract infections |
| Pharmacologic class | Echinocandin Antifungal | Azole Antifungal |
| How it works (label) | Micafungin is a member of the echinocandin class of antifungal agents [see Microbiology ( 12.4 )]. | n/a |
| Half-life (label) | n/a | Peak plasma concentrations (C max ) in fasted normal volunteers occur between 1 and 2 hours with a terminal plasma elimination half-life of approximately 30 hours (range: 20 to 50 hours) after oral administration. |
| Earliest approval on file (Drugs@FDA) | March 16, 2005 | January 29, 1990 |
| First generic approved | May 17, 2019 | July 29, 2004 |
| Generic labelers (NDC) | 10 labelers | 41 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | n/a | $0.380 per tablet (Fluconazole 200 mg tablet) |
| 12-month price change | n/a | -10% |
| Boxed warning | No | No |
| Shortage now | A presentation being discontinued | No current entry |
| Recalls recorded | 4 | 18 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,383 | 69,671 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
Do their labels mention each other?
Micafungin label, drug interactionsDrugs on Micafungin CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of micafungin with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin.
Micafungin label, drug interactionsDrugs on Micafungin in Sodium Chloride Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of Micafungin in Sodium Chloride Injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin.
Source: FDA drug labels via openFDA
What next?
- Alternatives to micafungin
- every medicine labeled for the same conditions